139 related articles for article (PubMed ID: 25933459)
1. Proptosis of eye: an atypical presentation of prostatic malignancy.
Amjad A; Osmani AH; Haider G
J Coll Physicians Surg Pak; 2015 Apr; 25 Suppl 1():S39-40. PubMed ID: 25933459
[TBL] [Abstract][Full Text] [Related]
2. Proptosis--an uncommon presentation of orbital metastases secondary to prostate cancer.
Vissamsetti B; McArdle PA; Adams CJ; Hotiana Z; Morton AL; Alexander RJ
Urol Int; 2007; 79(4):374-5; discussion 375. PubMed ID: 18025861
[TBL] [Abstract][Full Text] [Related]
3. Orbital metastasis as a first indication of prostate cancer: a case report.
Autorino R; Zito A; Di Giacomo F; Cosentino L; Quarto G; Di Lorenzo G; Mordente S; Pane U; Giordano A; D'Armiento M
Arch Ital Urol Androl; 2005 Jun; 77(2):109-10. PubMed ID: 16146273
[TBL] [Abstract][Full Text] [Related]
4. A case of orbital metastasis from prostatic carcinoma as an initial symptom.
Isshiki S; Cho S; Matsuno D; Sato N; Furuya Y
Hinyokika Kiyo; 2007 Mar; 53(3):193-5. PubMed ID: 17447492
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
6. Proptosis due to "isolated" soft tissue orbital metastasis of prostate carcinoma.
Nayyar R; Singh P; Panda S; Kashyap S; Gupta NP
Indian J Cancer; 2010; 47(1):74-6. PubMed ID: 20071798
[No Abstract] [Full Text] [Related]
7. Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
Patel V; Castell FA; Akinwunmi J; Francis I; Chandrasekharan L; Malhotra R
Orbit; 2010 Aug; 29(4):213-5. PubMed ID: 20812840
[TBL] [Abstract][Full Text] [Related]
8. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
9. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
[TBL] [Abstract][Full Text] [Related]
10. Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis.
Patel AR; Olson KB; Pienta KJ
Anticancer Res; 2005; 25(5):3521-2. PubMed ID: 16101173
[TBL] [Abstract][Full Text] [Related]
11. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer metastatic only to the penis.
Celebi MM; Venable DD; Nopajaroonsri C; Eastham JA
South Med J; 1997 Sep; 90(9):959-61. PubMed ID: 9305314
[TBL] [Abstract][Full Text] [Related]
13. [Retrorbital metastasis an initial manifestation of prostatic cancer].
Bonillo García MA; Queipo Zaragozá JA; Palmero Marti JA; Pacheco Bru JJ; Vera Sempere FJ; Jiménez Cruz JF
Actas Urol Esp; 2003; 27(7):562-5. PubMed ID: 12938590
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
17. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
18. Prostate adenocarcinoma with orbital metastasis in an HIV+ man.
Heintz J; Kahn B; Kramer A
Can J Urol; 2011 Apr; 18(2):5660-2. PubMed ID: 21504657
[TBL] [Abstract][Full Text] [Related]
19. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
20. [A case of prostatic carcinoma presenting as a metastatic orbital tumor].
Sakai H; Igawa T; Saha PK; Nomata K; Yushita Y; Kanetake H; Saito Y
Hinyokika Kiyo; 1992 Jan; 38(1):77-80. PubMed ID: 1546575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
